REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $565.2M as of December 31, 2022 to fund its operations into 2025. This cash runway guidance is based on the Company’s current operational plans and excludes the impact of any payments that may be received from AbbVie upon the achievement of development or commercial milestones under our RGX-314 collaboration.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RGNX:
- REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights
- Regenxbio announces ‘positive’ interim data from Phase I/II trial of RGX-111
- Regenxbio announces additional ‘positive’ interim data from CAMPSIITE trial
- Pathway Development Consortium announces publication on DMD
- Regenxbio announces Phase 1/2 trial of RGX-202 in Duchenne
